<DOC>
	<DOCNO>NCT00109954</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . In case , chemotherapy give artery ( hepatic artery ) bring blood tumor . Chemoembolization kill tumor cell block blood flow tumor keep chemotherapy drug near tumor . Internal radiation use radioactive material place directly near tumor kill tumor cell . It yet know whether hepatic arterial chemoembolization cisplatin effective internal radiation therapy treat liver cancer . PURPOSE : This randomized phase III trial study hepatic arterial chemoembolization cisplatin see well work compare internal radiation therapy treat patient advanced liver cancer remove surgery .</brief_summary>
	<brief_title>Hepatic Arterial Chemoembolization With Cisplatin Internal Radiation Therapy Treating Patients With Advanced Liver Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare time disease progression patient unresectable advanced hepatocellular carcinoma treat cisplatin-based trans-arterial chemoembolization v hepatic intra-arterial yttrium Y 90 glass microspheres ( TheraSphere® ) . - Compare health-related quality life patient treat regimen . - Compare safety regimens patient . Secondary - Compare survival patient treat regimen . - Compare tumor response CT scan patient treat regimen . - Compare treatment-related cost , term cost therapy number hospitalization day , patient . OUTLINE : This randomize study . Patients stratify accord extent tumor liver ( &lt; 50 % v ≥ 50 % ) presence portal hypertension ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo trans-arterial chemoembolization comprise intra-arterial ( IA ) infusion cisplatin 30-60 minute follow embolization hepatic artery ( brings blood tumor ) day 1 . Treatment repeat every 8-10 week absence disease progression unacceptable toxicity . - Arm II : Patients receive yttrium Y 90 glass microspheres ( TheraSphere® ) IA day 1 . Beginning 60 day first TheraSphere® treatment , patient may receive additional treatment TheraSphere® follow-up CT scan show progressive disease . Quality life assess baseline every 3 month thereafter . After completion study treatment , patient follow 30 day every 2 month 2 year . PROJECTED ACCRUAL : A total 120 patient ( 60 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Histologically cytologically confirm hepatocellular carcinoma ( HCC ) Confined liver Vascular liver mass presence cirrhosis Alphafetoprotein level &gt; 500 ng/mL Measurable disease At least 1 unidimensionally measurable lesion &gt; 20 mm spiral CT scan Unresectable disease , due tumor size extent presence cirrhosis No metastatic disease , include brain metastasis Locoregional lymph node metastasis allow No evidence potential delivery &gt; 16.5 miCi ( 30 Gy absorb dose ) radiotherapy lung either first administration yttrium Y 90 glass microspheres ( TheraSphere® ) cumulative delivery radiation lung multiple treatments* No evidence detectable technetium Tc 99m macroaggregated albumin ( Tc99m MAA ) flow stomach duodenum application establish angiographic technique stop flow* NOTE : *For patient randomize TheraSphere® arm PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy More 12 week Hematopoietic WBC &gt; 2,500/mm^3 Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 60,000/mm^3 No bleed diathesis correctable usual form therapy Hepatic See Disease Characteristics Bilirubin &lt; 2.0 mg/dL AST and/or ALT ≤ 5 time upper limit normal Hepatitis allow No portal hypertension hepatofugal flow Renal Creatinine &lt; 2.5 mg/dL Cardiovascular No symptomatic congestive heart failure No severe peripheral vascular disease would preclude catheterization Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective double barrier hormonal contraception least 30 day completion study treatment No ongoing active infection No uncontrolled illness No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No 1 prior systemic chemotherapy HCC More 4 week since prior IV chemotherapy recover More 1 year since prior hepatic arterial cisplatin More 4 month since prior hepatic arterial chemotherapy Endocrine therapy Not specify Radiotherapy No prior external hepatic radiotherapy HCC Surgery Not specify Other No concurrent therapy HCC No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
</DOC>